Science 37 Launches Infectious Disease Prevention Study in Just 12 Weeks

A biotech sponsor contracted Science 37 to help enroll patients in a global Phase 2/3 registrational study with 95+ sites in 30 countries. Acting as a virtual site, Science 37 worked alongside traditional sites to reach a broader patient population and accelerate time-to-market.

See how the Science 37 Direct-to-Patient Site  was the top enrolling site in the study, achieving more than 90% patient retention and a start-up time of 12 weeks across all 50 U.S. states.

Submit the form to watch the case study video.